United Therapeutics Reports Q3 2026 Financial Results
UNITED THERAPEUTICS Corp
Subscribe to track UTHR
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
š United Therapeutics Corp (UTHR) Q3 2026 Financial Results
ā¢ Revenues: $832.5M (+4% YoY vs. $799.5M in Q3 2025) ā¢ Net Income: $258.6M (-24% YoY vs. $338.7M in Q3 2025) ā¢ Diluted EPS: $5.71 (-20% YoY vs. $7.16 in Q3 2025) ā¢ Key Growth Driver: Tyvaso DPI sales rose 13% YoY to $378.5M, offsetting a 12% decline in Nebulized Tyvaso.
Comprehensive Analysis
Executive Summary
On November 4, 2026, United Therapeutics Corporation (Nasdaq: UTHR) filed an Item 2.02 Form 8-K reporting financial results for the third quarter ended September 30, 2026.
Key Financial Highlights
- Total Revenues: $832.5 million, up 4.1% year-over-year compared to $799.5 million in Q3 2025.
- Net Income: $258.6 million, down 23.6% compared to $338.7 million in Q3 2025.
- Diluted EPS: $5.71 per share, down 20.3% compared to $7.16 per share in Q3 2025.
- Basic EPS: $6.06 per share, compared to $7.73 per share in Q3 2025.
Product Revenue Breakdown
| Product | Q3 2026 ($M) | Q3 2025 ($M) | YoY Change (%) |
|---|---|---|---|
| Tyvaso DPI | $378.5 | $336.2 | +13% |
| Nebulized Tyvaso | $125.3 | $141.8 | -12% |
| Total Tyvaso | $503.8 | $478.0 | +5% |
| Orenitram | $145.0 | $131.1 | +11% |
| Remodulin | $122.0 | $125.9 | -3% |
| Unituxin | $52.3 | $47.9 | +9% |
| Adcirca | $4.5 | $9.7 | -54% |
| Other | $4.9 | $6.9 | -29% |
| Total Revenues | $832.5 | $799.5 | +4% |
Operational & Commercial Commentary
- Tyvaso Franchise Dynamics: Growth in Tyvaso DPI was driven primarily by an increase in quantities sold ($43.9 million impact) and price increases, partially offset by higher gross-to-net deductions. Conversely, Nebulized Tyvaso declined due to lower U.S. volume, reflecting ongoing migration to the DPI formulation and market competition.
- Competition Impact: Management noted that the availability of competitive therapies negatively affected sales across Nebulized Tyvaso, Tyvaso DPI, and Remodulin during the quarter.
- Orenitram Expansion: Revenue growth of 11% was propelled by a $14.9 million increase in quantities sold and higher realized pricing, net of gross-to-net deductions.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.